Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Duff, K. et al., Increased amyloid-β 42(43) in brains of mice expressing mutant presenilin 1. Nature 383 , 710–713 (1996). Article CAS Google Scholar ...

Mild cognitive impairment is linked to blood vessel dysfunction in the brain's temporal lobes—the seat of memory—according to ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

The relationship between amyloid β (Aβ) deposition and cognitive function is unclear: previous studies have included participants with normal cognition without knowledge of their Aβ deposition ...

The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners ...

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...

The litany of failed trials of amyloid-targeting drugs for Alzheimer's disease has added another verse, as Roche concedes that its crenezumab candidate was unable to slow cognitive decline in ...

Mild cognitive impairment is linked to blood vessel dysfunction in the brain's temporal lobes -- the seat of memory -- according to a new study. The findings, seen in people with and without signs of ...

The drugs attack so-called amyloid plaques in the brain. But how can we reliably and cost effectively diagnose the presence of amyloid plaques in patients who show up at memory clinics with slight ...

Tafamidis not only improves survival but also mitigates cardiac structural changes and functional declines, underscoring its ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...